CONCORD, Mass., October 20, 2022–(BUSINESS WIRE)–Tremeau Pharmaceuticals today announced that it will host a Key Opinion Leader (KOL) webinar to discuss the unmet medical need in migraine management and the potential role of rofecoxib, a COX-2 selective nonsteroidal anti-inflammatory drug. inflammatory drug (NSAIDs), in the treatment landscape on Tuesday, October 25, 2022 at 11:00 a.m. EST. A live Q&A session will follow the official presentation. To register for the event, please click here.
The KOL portion of the event will include a presentation by Charles E. Argoff, MD, professor of neurology at Albany Medical College and director of the Comprehensive Pain Center and director of the Pain Management Fellowship at Albany Medical Center at New York. Dr. Argoff is a member of the American Academy of Neurology, the International Association for the Study of Pain, and the American Academy of Pain Medicine (VP of Scientific Affairs), among other professional organizations. Dr. Argoff is one of the editors of the recently published textbook Raj’s Practical Management of Pain, 6th Edition. Co-author of Defeat Chronic Pain Now, published for chronic pain sufferers, he also recently published the third edition of Pain Management Secrets. Dr. Argoff received his medical degree from Northwestern University Medical School in Chicago, Illinois. He completed his medical internship in internal medicine and residency in neurology at Stony Brook University in New York and a fellowship in neurology at the National Institutes of Health in Bethesda, Maryland.
In addition, Tremeau Founder and CEO Bradford C. Sippy will discuss the company’s development pipeline, including the Phase III-ready TRM-201 (rofecoxib). Previously marketed as VIOXX, rofecoxib has been shown to have a well-established efficacy profile in multiple indications, including migraine. Rofecoxib has been shown to have greater penetration of the blood-brain barrier than any COX-2 selective NSAID currently available in the United States and has demonstrated efficacy in migraine, whether or not there has been a history of previous response to other NSAIDs. It is the only COX-2 selective NSAID ever approved in the United States to demonstrate a reduced risk of gastrointestinal bleeding compared to a traditional NSAID in a controlled trial.
About TRM-201 (rofecoxib)
TRM-201 is an investigational non-opioid pain treatment containing rofecoxib. Previously marketed as VIOXX, rofecoxib has been shown to be a highly potent cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drug, or NSAID, with a well-established efficacy profile in multiple indications. , including acute migraine. Rofecoxib has been shown to have greater penetration of the blood-brain barrier than any COX-2 selective NSAID currently available in the United States and has demonstrated efficacy in migraine, whether or not there has been a history of previous response to other NSAIDs. Rofecoxib has been shown to have no effect on bleeding time and is the only COX-2 selective NSAID ever approved in the United States to demonstrate a reduced risk of gastrointestinal bleeding compared to a traditional NSAID in a controlled trial. VIOXX was voluntarily taken off the market in 2004 due to cardiovascular safety concerns. It has since been shown in multiple studies, often independent of the industry, that cardiovascular safety is a dose and duration dependent risk of all NSAIDs.
About Tremeau Pharmaceuticals
Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain therapies for well-defined patient populations with significant unmet needs.
Tremeau’s unique approach to acute and chronic pain in certain conditions is rooted in the mechanism of action, documented efficacy and clinically differentiated profile of COX-2 selective NSAIDs.
Tremeau’s lead clinical-stage product, TRM-201 (rofecoxib), is a COX-2-selective NSAID and potent non-opioid analgesic with a well-established benefit-risk profile.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20221020005171/en/
#Tremeau #Pharmaceuticals #Host #Key #Opinion #Leader #Webinar #Rofecoxib #Migraine #Management #Tuesday #October